These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 15076241)
41. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART. Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401 [TBL] [Abstract][Full Text] [Related]
42. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration. Ezinga M; Wetzels JF; Bosch ME; van der Ven AJ; Burger DM Antivir Ther; 2014; 19(8):765-71. PubMed ID: 24584104 [TBL] [Abstract][Full Text] [Related]
43. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. Day SL; Leake Date HA; Bannister A; Hankins M; Fisher M J Acquir Immune Defic Syndr; 2005 Mar; 38(3):301-4. PubMed ID: 15735448 [TBL] [Abstract][Full Text] [Related]
44. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review. Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J Int J STD AIDS; 2005 Sep; 16(9):646-8. PubMed ID: 16176639 [TBL] [Abstract][Full Text] [Related]
45. Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy. Pavie J; Scemla A; Bouldouyre MA; Pillebout E; Verine J; Molina JM AIDS Patient Care STDS; 2011 Aug; 25(8):457-60. PubMed ID: 21751874 [TBL] [Abstract][Full Text] [Related]
46. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine? Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J J Acquir Immune Defic Syndr; 2004 Apr; 35(4):427-8. PubMed ID: 15097160 [No Abstract] [Full Text] [Related]
52. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. Kinai E; Hanabusa H AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280 [TBL] [Abstract][Full Text] [Related]
53. [Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects]. MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011603 [No Abstract] [Full Text] [Related]
54. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Squires K; Pozniak AL; Pierone G; Steinhart CR; Berger D; Bellos NC; Becker SL; Wulfsohn M; Miller MD; Toole JJ; Coakley DF; Cheng A; Ann Intern Med; 2003 Sep; 139(5 Pt 1):313-20. PubMed ID: 12965939 [TBL] [Abstract][Full Text] [Related]
55. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328 [TBL] [Abstract][Full Text] [Related]
59. [Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and how frequently]. Barril Cuadrado G; de Los Santos Gil I Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():55-61. PubMed ID: 19195438 [TBL] [Abstract][Full Text] [Related]